Sign in
Taking people in United StatesPhase 2

Study of Tirzepatide for Recovery and Alcohol Use Management

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston and Jamaica Plain, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
15 Sept 2025
Expected to end
1 Jul 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tirzepatide
  • Saline Placebo
Record updated
9 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • English speaking adults aged 18 and above
  • Diagnosed with current DSM-5 alcohol use disorder
  • Willing and able to physically travel to BWH CCI outpatient facilities for study visits

Who cannot take part

  • Use of any GLP-1 agonist medications in the prior 3 months
  • Anticipating receipt of any other GLP-1 agonist medications during the trial
  • Anticipated to be enrolled in another clinical drug trial during participation in this trial
  • Psychotic disorder, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent
  • Any lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating, or avoidant/restrictive food intake disorder
  • Current or lifetime diagnosis of Type 1 or Type 2 diabetes
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • Untreated cholelithiasis or gallbladder disease
  • Acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or congestive heart failure in the last 90 days
  • Uncontrolled hypertension at baseline, as indicated by an average blood pressure reading of >180/110 after three successive readings
  • History of inflammatory bowel disease, bariatric surgery, pancreatitis, diabetic gastroparesis, or non-arteritic anterior ischemic optic neuropathy
  • History of hypersensitivity or allergy to tirzepatide
  • Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant
  • Current (or within 30 days of enrollment) use of any anti-obesity medications or medications with glucose lowering properties (including GLP-1 analogues, sulfonylurea, insulin, metformin, thiazolidinediones, dipeptidyl peptidase-4 (DPP-IV) inhibitors, or sodium-glucose cotransporter-2 (SGLT-2) inhibitors)
  • Current hypoglycemia as indicated by a blood sugar level of ≤70 mg/dL measured at the baseline visit
  • Triglycerides ≥500 mg/dL
  • Renal impairment as indicated by eGFR of <30
  • CIWA score at screening ≥ 8
  • BMI<23 mg/kg2
  • Calcitonin ≥ 50 ng/L
  • Liver function test greater than 5 times upper normal limit
  • Pregnant or breastfeeding

This trial is currently available in United States.

  • Brigham and Women's HospitalBoston, United StatesContact: Joji Suzuki, MDNo longer taking part
  • Brigham and Women's Faulkner HospitalJamaica Plain, United StatesContact: Joji Suzuki, MDTaking people

About the trial

What the trial wants to find out

This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.

The 2 groups in the trial

  • TirzepatideTreatment being tested

    This arm will receive tirzepatide (n=10) weekly 2.5mg injections for 4 weeks.

  • Saline PlaceboPlacebo, for comparison

    This arm will receive saline placebo injections (n=10) weekly for 4 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tirzepatide for the Treatment of Alcohol Use Disorder: A Pilot Randomized Controlled Trial
Record updated
9 July 2026